These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 30504406

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, Volante M, Buttitta F, Guerini-Rocco E, Righi L, D'antuono T, Scagliotti GV, Pinto C, De Rosa G, Papotti M.
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, Hofman P.
    PLoS One; 2017 Nov; 12(8):e0183023. PubMed ID: 28797130
    [Abstract] [Full Text] [Related]

  • 5. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
    Savic S, Berezowska S, Eppenberger-Castori S, Cathomas G, Diebold J, Fleischmann A, Jochum W, Komminoth P, McKee T, Letovanec I, Jasarevic Z, Rössle M, Singer G, von Gunten M, Zettl A, Zweifel R, Soltermann A, Bubendorf L.
    Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385
    [Abstract] [Full Text] [Related]

  • 6. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
    Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Netto GJ, Hoque MO, Brunelli M, Martignoni G, Haffner MC, Moretta F, Pegoraro MC, Cavazza A, Samogin G, Furlan V, Mariotti FR, Vacca P, Moretta L, Bogina G.
    Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
    [Abstract] [Full Text] [Related]

  • 7. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.
    Shigeta N, Murakami S, Yokose T, Isaka T, Shinada K, Nagashima T, Adachi H, Shigefuku S, Murakami K, Miura J, Kikunishi N, Watabe K, Saito H, Ito H.
    Thorac Cancer; 2024 Jun; 15(17):1343-1349. PubMed ID: 38698758
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P.
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [Abstract] [Full Text] [Related]

  • 11. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.
    J Clin Oncol; 2017 Dec 01; 35(34):3867-3876. PubMed ID: 29053400
    [Abstract] [Full Text] [Related]

  • 12. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
    Skov BG.
    Appl Immunohistochem Mol Morphol; 2021 Jan 01; 29(1):49-55. PubMed ID: 31913160
    [Abstract] [Full Text] [Related]

  • 13. Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC.
    Sughayer MA, Alnaimy F, Alsughayer AM, Qamhia N.
    Appl Immunohistochem Mol Morphol; 2019 Oct 01; 27(9):663-666. PubMed ID: 30024424
    [Abstract] [Full Text] [Related]

  • 14. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
    Yu SL, Hsiao YJ, Cooper WA, Choi YL, Avilés-Salas A, Chou TY, Coudry R, Raskin GA, Fox SB, Huang CC, Jeon YK, Ko YH, Ku WH, Kwon GY, Leslie C, Lin MC, Lou PJ, Scapulatempo-Neto C, Mendoza Ramírez S, Savelov N, Shim HS, Lara Torres CO, Cunha IW, Zavalishina L, Chen YM.
    Pathology; 2023 Feb 01; 55(1):19-30. PubMed ID: 36319485
    [Abstract] [Full Text] [Related]

  • 15. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
    Ivanova M, Frascarelli C, Cerbelli B, Pignataro MG, Pernazza A, Venetis K, Sajjadi E, Criscitiello C, Curigliano G, Guerini-Rocco E, Graziano P, Martini M, d'Amati G, Fusco N.
    Hum Pathol; 2024 Feb 01; 144():22-27. PubMed ID: 38278450
    [Abstract] [Full Text] [Related]

  • 16. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
    Zhou C, Srivastava MK, Xu H, Felip E, Wakelee H, Altorki N, Reck M, Liersch R, Kryzhanivska A, Oizumi S, Tanaka H, Hamm J, McCune SL, Bennett E, Gitlitz B, McNally V, Ballinger M, McCleland M, Zou W, Das Thakur M, Novello S.
    J Immunother Cancer; 2023 Oct 01; 11(10):. PubMed ID: 37903590
    [Abstract] [Full Text] [Related]

  • 17. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD, Abengozar-Muela M, Echeveste JI, Subtil JC, Bertó J, Gúrpide A, Calvo A, de Andrea CE.
    Cancer Cytopathol; 2019 Jul 01; 127(7):470-480. PubMed ID: 31245924
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
    Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, Tixier L, Danel C, Damiola F, Damotte D, Penault-Llorca F, Lantuéjoul S.
    Ann Oncol; 2018 Apr 01; 29(4):953-958. PubMed ID: 29351573
    [Abstract] [Full Text] [Related]

  • 20. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G.
    Hum Pathol; 2019 May 01; 87():11-17. PubMed ID: 30794891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.